Several landmark phase 3 trials have demonstrated the efficacy and safety of NOACs reducing the risk of stroke and mortality in patients living with AFib, as well as VTE.3,4,5,6
Granger et al conducted a randomised, double-blind study comparing apixaban (5mg twice daily) with warfarin (target international normalised ratio [INR] 2.0 to...